Diabetes Duration and Subclinical Myocardial Injury: The Atherosclerosis Risk in Communities Study (ARIC)

Carine E Hamo1, Justin B Echouffo-Tcheugui2, Sui Zhang3

  • 1Division of Cardiology, Johns Hopkins University, Baltimore, MD, USA.

Clinical Chemistry
|July 29, 2022
PubMed

Insights

Longer diabetes duration significantly increases the risk of subclinical myocardial injury, indicated by elevated high-sensitivity cardiac troponin levels. Early diabetes prevention may mitigate this cardiac damage.

Area of Science:

  • Cardiology
  • Endocrinology
  • Public Health

Background:

  • Diabetes mellitus is a known risk factor for cardiovascular complications, including heart failure.
  • The relationship between the duration of diabetes and subclinical myocardial injury requires further investigation.

Purpose of the Study:

  • To examine the association between diabetes duration and subclinical myocardial injury.
  • To assess subclinical myocardial injury using high-sensitivity cardiac troponin T (hs-cTnT) levels.

Main Methods:

  • Analysis of 9052 participants from The Atherosclerosis Risk in Communities Study (ARIC).
  • Diabetes duration was determined by diagnosis age or status across study visits.
  • Multinomial logistic regression was used to associate diabetes duration with hs-cTnT levels, adjusting for covariates.

Main Results:

  • Prevalence of elevated hs-cTnT increased with longer diabetes duration (0-4.9 years: 12%; ≥15 years: 31%).
  • New-onset diabetes at Visit 4 showed a 1.92x higher risk of elevated hs-cTnT.
  • Diabetes duration of ≥15 years was associated with a 9.29x higher risk of elevated hs-cTnT compared to no diabetes.

Conclusions:

  • Prolonged diabetes duration is a significant predictor of subclinical myocardial injury.
  • Interventions aimed at preventing or delaying diabetes onset may reduce early cardiac damage.
Abstract

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
50
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
35
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
29
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
30
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
21
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
28